U.S. markets closed

Evolus, Inc. (EOLS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.42-0.32 (-3.66%)
At close: 4:00PM EDT

8.50 +0.08 (0.95%)
After hours: 7:59PM EDT

Evolus, Inc.

520 Newport Center Drive
Suite 1200
Newport Beach, CA 92660
United States
949 284 4555
http://www.evolus.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees119

Key Executives

NameTitlePayExercisedYear Born
Mr. David MoatazediPres, CEO & Director1.25MN/A1978
Ms. Lauren P. SilvernailCFO & Exec. VP of Corp. Devel.633.18kN/A1958
Dr. Rui Avelar Dip.SportMed, M.D., C.CFPChief Medical Officer and Head of R&D631.26kN/A1962
Mr. Ashwin K. AgarwalVP of Fin., Investor Relations & TreasuryN/AN/AN/A
Mr. Jeffrey J. PlumerGen. CounselN/AN/AN/A
Mr. Kurt KnabVP of SalesN/AN/AN/A
Ms. Crystal MuilenburgChief Marketing OfficerN/AN/A1980
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.

Corporate Governance

Evolus, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.